RESEARCH REPORT, 2026
State of MedTech Regulatory Automation
A primary-research report on how MedTech teams are compressing regulatory timelines and accelerating new product development, built for regulatory and quality leaders.
WHAT'S INSIDE
Four chapters built for regulatory and quality leaders
Why regulatory uncertainty drags on innovation timelines, from FDA 21 CFR Part 820 to EU MDR and IVDR, and where QMS maturity gaps still slow new product development.
A benchmark from paper-based QMS to AI-assisted regulatory intelligence, with a maturity model and peer benchmarks for gauging technology readiness.
How time-to-submission and review velocity change across device programs, covering 510(k) submission timelines and audit readiness.
A step-by-step framework for moving a regulatory function from reactive to automated without disrupting active submissions, covering change management and phased rollout.
GET THE REPORT
Get the 2026 whitepaper
Primary research. Peer-reviewed benchmarks. Secure and private.
DESIGNED FOR
Built for the people who own the submission
Regulatory Affairs VPs and Directors
Benchmark your team's submission timelines and automation maturity against peers building the same devices.
Quality and Compliance leaders
See where QMS maturity gaps create rework and how automation closes them without adding headcount.
MedTech founders and CEOs
Understand how regulatory automation changes the runway between first concept and first-time clearance.
NPD and Engineering leaders
See where regulatory uncertainty adds friction to the product development timeline, and how to plan around it.
Move at the Speed of Innovation
See QualiVerse® against your own program
Talk to the regulatory team behind QualiVerse®, not a chatbot.